A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma.

we constructed a novel immune checkpoints-based system for LUAD, which predicts prognosis and immunotherapeutic implications. We believe that these findings will not only aid in clinical management but will also shed some light on screening appropriate patients for immunotherapy.